Recent developments indicate a heightened regulatory focus on psychedelic biotech firms, particularly concerning their promotional strategies on platforms like YouTube.
In parallel, major pharmaceutical players Biogen and Eli Lilly are actively pursuing acquisitions, potentially reshaping the landscape of the biotech sector.
Additionally, Doctors Without Borders has voiced significant concerns regarding Gilead's practices, adding another layer of scrutiny to the industry.